AI-assisted research analysis by FutureKnowledge. Sources checked 22 October 2026. This is not investment advice.
Reviewed by FutureKnowledge: figures, dates and attributions were checked against the linked sources before publication.
Swedish buyout firm EQT has agreed to take Qiagen private at €46.50 a share in cash, valuing the DAX-listed molecular testing company at about €10.8 billion ($12.1 billion) including net debt. Qiagen’s boards unanimously back the offer, which is co-funded by Abu Dhabi Investment Authority (ADIA) and Canada’s CPP Investments and is expected to close in mid-2027.
What happened in the EQT Qiagen deal
Qiagen, based in Venlo in the Netherlands, announced late on 21 October that it had signed a business combination agreement with a vehicle controlled by the EQT XI fund. According to the company’s ad hoc disclosure, the bidder will make a voluntary all-cash public takeover offer for all shares. The price is a 40.3% premium to the €33.15 Xetra close on 8 July 2026, the last trading day before reports of private equity interest, and 46.9% above the three-month volume-weighted average up to that date.
The headline value differs by source because of what is counted. Qiagen’s release gives an enterprise value of about €10.8 billion, which includes roughly $1.1 billion of net debt. Reuters and Finimize instead quote about €9.6 billion, which reflects the value of the shares alone. Both figures describe the same €46.50 offer.
Alongside the deal, Qiagen published preliminary third-quarter figures: net sales of $548 million and adjusted diluted earnings per share of $0.65. Investing.com reported that both numbers were above analyst expectations of $536 million and $0.62. Qiagen also suspended its full-year 2026 outlook while the transaction is pending and said full results will follow on 4 November, without a conference call.
Why Qiagen agreed to a buyout
The agreement ends a sale process that ran for months. Börsen-Zeitung reported that KKR, Advent, Bain and TPG had also shown interest and that Goldman Sachs ran the process; on 20 October Investing.com, citing Bloomberg, reported that KKR had also bid and that Qiagen’s shares jumped more than 7% on news of advanced EQT talks.
In the release, chief executive Jonathan Pratt argued that private ownership would let the company move faster and invest more freely in its strongest opportunities. EQT says it has committed to Qiagen’s strategy, brands, operating footprint, research and development and employees, and that the company will keep its name. Qiagen employs about 5,400 people and serves more than 500,000 customers in life sciences and molecular diagnostics, according to the release.
There is also history. Börsen-Zeitung noted that Thermo Fisher’s roughly $12 billion bid in 2020 failed after opposition from an activist investor kept acceptances below the required level. This time the structure is different: the minimum acceptance is 50% of shares plus one, and the plan relies on post-closing measures approved at an extraordinary general meeting rather than a high tender threshold.
How the takeover is structured and financed
- Conditions: 50% plus one share tendered, approval of resolutions at an extraordinary general meeting, merger control and foreign investment clearances, and a separate implementation decision by Qiagen’s boards (ad hoc disclosure).
- Vote threshold: if at least 80% of votes cast approve the post-closing measures, the boards will proceed. Below that, they may still proceed if they judge it in the company’s interest and there is substantial majority support, and may weigh whether votes come from longer-term holders or recent buyers, ad-hoc-news reported from the filing.
- Financing: committed equity and debt with no financing condition. Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole and UniCredit are arranging the debt. Börsen-Zeitung put the split at about 55% equity and 45% bank debt.
- Delisting: shareholders who do not tender would receive a cash distribution equal to the offer price, less withholding taxes, and the Frankfurt and NYSE listings would end, removing Qiagen from the DAX.
- Delay clause: if regulatory approvals hold up closing beyond 10 months, Qiagen may pay an interim dividend of up to $0.47 a share without reducing the offer price.
How Qiagen shares reacted
Because takeover talk had already lifted the stock, the remaining upside is small. Reuters put the offer at an 8.6% premium to the last close before the announcement. Börsen-Zeitung reported that Qiagen shares rose about 1% to €45.10 in Frankfurt on Thursday, leaving them a little below the offer price, and noted that the company’s market value had nearly doubled since May. Finimize said the US-listed shares moved only about 0.7% after hours. It linked the narrow gap to the long wait and regulatory risk.
What it means for businesses and investors
Börsen-Zeitung described the deal as the largest private equity take-private in German history. It shows buyout funds and sovereign investors are still willing to pay up for diagnostics businesses with recurring consumables revenue. EQT says it has invested more than €30 billion in over 210 healthcare companies, ad-hoc-news reported.
The deal also fits a busy year for strategic moves among large companies, from Salesforce’s $5.66 billion purchase of Braze to Abbott’s plan to spin off its nutrition business.
Who is more or less exposed
- More exposed: index funds and benchmarked investors, which will need to adjust when Qiagen leaves the DAX. Short-term holders also carry the risk that the deal is delayed or blocked.
- Exposed to change: suppliers and laboratory customers, as private owners often revisit pricing and costs.
- Less exposed: long-term holders who accept the cash offer, assuming the conditions are met. Their main remaining risk is the time value of money until mid-2027.
Scenarios to watch
These are conditional scenarios, not predictions.
| If… | Then… |
|---|---|
| Acceptances clear 50% and the EGM vote is above 80% | The post-closing measures proceed and the deal moves to regulatory clearance as planned. |
| The EGM vote falls below 80% | The boards decide whether support is still substantial enough to proceed, which creates uncertainty. |
| Competition or foreign-investment reviews take longer than 10 months | Qiagen may pay an interim dividend of up to $0.47 a share and closing could move beyond mid-2027. |
| A rival bidder returns with a higher offer | The agreed terms could be challenged. No rival offer had been announced as of 22 October. |
What to watch next
- BaFin’s approval of the offer document, which starts the acceptance period and the parallel US tender offer filed with the SEC.
- Qiagen’s full third-quarter results on 4 November and its formal board position statement.
- The date of the extraordinary general meeting and the size of the vote.
Bottom line
EQT’s €46.50-a-share offer gives Qiagen shareholders a 40% premium to the price before bid talk began, with board support and committed financing. Because the shares already trade close to the offer, the questions now are the shareholder vote, regulatory timing and whether the deal closes on schedule in mid-2027.
Method note: This analysis compares Qiagen’s ad hoc disclosure and Business Wire releases on the EQT agreement and preliminary Q3 results with reporting from Reuters, Börsen-Zeitung, Finimize, Investing.com and ad-hoc-news. Where sources gave different headline values, we used the company’s enterprise value and explained the equity-value figure.